Can I join?
Approximately 400 participants in study centers across Europe, North America, and Asia-Pacific are expected to take part. You may be able to take part if you:
- Are 40–80 years of age
- Have been diagnosed with COPD with chronic bronchitis
- Have been using inhaler maintenance therapy for at least 3 months (ongoing treatment you use regularly to help manage your COPD)
- Have experienced lung flare-ups (COPD symptoms getting noticeably worse) in the past year
- Are a current or ex-smoker
To check if you meet the entry criteria for the SCALA Study, please complete the participation checklist. If the results show that you may be suitable for the study, contact your nearest study center to discuss enrollment.
What happens next?
You will need to visit a study center and be evaluated in person before you can participate in the study. Before joining the study, the study team will explain the study to you in detail and tell you what to expect.
You must also agree to, and sign an Informed Consent Form, or ICF. This document outlines everything you need to know about the study, including potential risks and benefits, as well as your rights and responsibilities while taking part.
Is the SCALA Study right for me?
Taking part in clinical research requires careful thought. Before you decide whether to participate, ask the study team any questions you may have to ensure you make an informed decision.
Keep in mind, there is no guarantee that you will receive any medical benefit from taking part in this study. And remember, clinical studies are voluntary. You are free to leave at any time and for any reason, with no penalty to you.
For people with COPD, and with people with COPD
UCB has been working alongside people with COPD and lung disease patient organizations. This collaboration has helped to tailor the study to meet the needs of people living with this condition.
Through multiple meetings, feedback sessions, and document reviews, people with COPD have provided important contributions to the study design and materials. These insights and guidance have been invaluable and are shaping the future development strategy of the study drug. UCB continues to engage with the COPD community to foster ongoing collaboration.
Interested?
See if you may qualifyUseful links
By selecting the button below you acknowledge you are leaving the SCALA Study website and continuing to another website not covered under its privacy policy.
Proceed to websiteSelecting this link will open a new message in your default email provider. By proceeding, you acknowledge you are leaving the SCALA Study website and continuing to another provider not covered under its privacy policy.
Proceed